IGC Pharma (IGC) Short term Debt (2011 - 2026)

IGC Pharma (IGC) posted quarterly Short term Debt of $726000.0 for Q1 2026, up 303.33% quarter-over-quarter from $180000.0 in Q4 2025.

IGC Pharma (IGC) Short term Debt (2011 - 2026) Analysis & Trends

IGC Pharma (IGC) has reported Short term Debt for 11 consecutive years, with $726000.0 the latest figure, recorded in Q1 2026.

In Q1 2026, Short term Debt changed N/A year-over-year to $726000.0; the TTM figure through Mar 2026 stood at $726000.0 (changed N/A YoY), while the FY2026 annual figure was $726000.0, changed N/A from the prior year.
Short term Debt grew to $726000.0 in Q1 2026 per IGC's latest filing, from $180000.0 in the prior quarter.
Across five years, Short term Debt topped out at $726000.0 in Q1 2026 and bottomed at $3000.0 in Q1 2022.
Historically, Short term Debt has averaged $228000.0 across 3 years, with a median of $91500.0 in 2022.
On a YoY basis, Short term Debt climbed as much as 0.0% in 2022 and fell as far as 99.01% in 2022.
IGC Pharma's Short term Debt stood at $3000.0 in 2022, then soared by 5900.0% to $180000.0 in 2025, then jumped by 303.33% to $726000.0 in 2026.
Business Quant data shows IGC's Short term Debt at $726000.0 in Q1 2026, $180000.0 in Q4 2025, and $3000.0 in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.99 Bn	132.14 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.80 Bn	78.80 Bn	3.93 Bn
3	Argenx Se	65.38 Bn	60.19 Bn	1.37 Bn
4	Moderna	60.70 Bn	55.56 Bn	52.00 Mn
5	BeOne Medicines	42.22 Bn	37.12 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.67 Bn	28.36 Bn	992.69 Mn
7	BioNTech SE	28.45 Bn	10.06 Bn	668.28 Mn
8	Insmed	27.47 Bn	26.31 Bn	358.27 Mn
9	Royalty Pharma	27.21 Bn	26.37 Bn	-
10	IGC Pharma	28.10 Mn	27.84 Mn	-

Download Data